Medtide Inc (3880) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Medtide Inc stock HK$31.33, price HK$19.02, upside +64.7%, quality 69 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Medtide Inc
3880 · HKCheap (39% below fair value) and solid company, but falling price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
16‑month range HK$18.53 – HK$40.64 · fair‑value band HK$19.74 – HK$39.25 · the HK$19.02 price screens below the HK$31.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Every Wednesday you see whether Medtide is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services.
Show moreShow less
It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products.
Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia.
The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
Stock analysis
Medtide Inc (3880) currently trades at HK$19.02, while our model-based Fair Value estimate is HK$31.33, implying the stock looks roughly 39% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$57.89 per share, and 18 of the 24 models we run sit above the HK$19.02 price.
Bear case: the Asset-Based group reads lowest at HK$8.35, and 6 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: HK$19.74 (bear) to HK$39.25 (bull), the price of HK$19.02 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medtide Inc reported revenue of 570M CNY in FY2025 versus 282M CNY in FY2021, a compound +19.2%/yr. Reported net income was 217M CNY in FY2025, compounding +28.3%/yr from FY2021.
Key figures
Market cap HK$2.7B (≈ $344M) Small · P/E ratio 14.7 · P/S ratio 5.62 · Net margin 38.1% · Return on equity 10.9% · Return on assets (EBIT) 10.7% (5-year average) · Operating margin 29.7% · Revenue (TTM) 551M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 65%, 3880 screens cheaper than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 3880, get fair value alerts →
Compare Medtide Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 3880 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 3880 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 3880 |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs 3880 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 3880 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 3880 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 3880 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 3880 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 3880 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 3880 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medtide Inc (3880) overvalued or undervalued?
What is the fair value of 3880?
What is the quality score of 3880?
What is the price target for Medtide Inc (3880)?
What is the Medtide Inc stock forecast for 2026?
What is the revenue of Medtide Inc (3880)?
What growth is priced into Medtide Inc (3880)?
What discount rate (WACC) does the fair value of 3880 use?
What is a reverse DCF?
How much growth has Medtide Inc (3880) delivered so far?
How fast is the sector of Medtide Inc (3880) growing?
What is the free cash flow yield of Medtide Inc (3880)?
What is the intrinsic value of Medtide Inc (3880)?
Is Medtide Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 3880?
How much is Medtide Inc worth?
What do the bullish and bearish scenarios say about 3880?
What is the P/E ratio of 3880?
How solid is the balance sheet of Medtide Inc (3880)?
How far is 3880 from its 52-week high?
Which stocks are comparable to Medtide Inc?
Is Medtide Inc stock attractive at the current price?
How is the fair value of 3880 calculated?
Is it still worth investing in stocks now?
What is the share price of Medtide Inc (3880)?
What should I pay attention to with Medtide Inc right now?
Key figures of Medtide Inc
How large is the market capitalisation of Medtide Inc (3880)?
What is the P/S ratio of Medtide Inc (3880)?
What is the net margin of Medtide Inc (3880)?
What is the return on equity of Medtide Inc (3880)?
What is the EBIT return on assets of Medtide Inc (3880)?
What is the operating margin of Medtide Inc (3880)?
How fast is revenue growing at Medtide Inc (3880)?
How fast are earnings growing at Medtide Inc (3880)?
How much net debt does Medtide Inc (3880) carry?
Watch Medtide Inc in the live analysis
One click puts Medtide Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.